Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeoVax Labs, Inc. (GOVX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, giving investors a structured view of its capital markets activity, governance decisions, and development funding. As a smaller reporting company, GeoVax files registration statements, current reports, and proxy materials that outline its financing transactions, stockholder approvals, and contractual arrangements.
Through registration statements on Form S-1 and Form S-3, GeoVax registers offerings of common stock and warrants, as well as the resale of warrant shares issued in private placements. These filings describe offerings such as registered direct financings and concurrent private placements of common warrants, the number of shares and warrants involved, and intended uses of proceeds, including research and development, manufacturing, clinical studies, capital expenditures, and working capital.
Form 8-K current reports provide details on material events, including the pricing and closing of offerings, entry into placement agency and purchase agreements, government contract developments, and the release of quarterly financial results. 8-K filings also cover special stockholder meetings and the outcomes of votes on proposals such as warrant share issuance approvals and reverse stock split authorizations.
Proxy materials, such as the DEF 14A special meeting proxy statement, outline proposals submitted to stockholders, the rationale for actions like reverse stock splits or warrant exercise approvals, and the mechanics of voting. In addition, Form 25 filings document the removal from listing and/or registration of specific GeoVax securities, such as warrants, from Nasdaq Stock Market LLC.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex documents in plain language. Investors can quickly see the key terms of financing agreements, understand the implications of stockholder votes, and track how government contracts like the BARDA/Project NextGen award are reflected in the company’s disclosures. Real-time updates from EDGAR ensure that new 8-Ks, S-1s, proxy statements, and other filings are available promptly, while dedicated sections for warrant-related disclosures and capital structure changes help users follow the evolution of GOVX’s securities over time.
GeoVax Labs, Inc. files a prospectus supplement that currently permits additional at-the-market sales of its common stock of up to approximately $3,116,227 through A.G.P./Alliance Global Partners under an existing Form S-3 program. This updates an earlier $30,000,000 at-the-market facility under which the company has already sold 4,525,449 shares for $9,269,560.
The supplement reflects limits under General Instruction I.B.6 of Form S-3, tied to GeoVax’s public float. The aggregate market value of common stock held by non-affiliates is stated as $17,804,611, based on 1,728,603 non-affiliate shares at $10.30 per share as of December 8, 2025, and the company notes it has raised $2,818,643 under this instruction in the past twelve months. GeoVax’s stock trades on the Nasdaq Capital Market under the symbol GOVX, with a last reported price of $3.15 on January 23, 2026.
GeoVax Labs, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock effective upon filing a Certificate of Amendment on January 9, 2026. Every twenty-five shares of existing common stock were automatically combined into one share of new common stock, with the par value per share remaining $0.001.
No fractional shares were issued; any fractional amounts were rounded up to the next whole share. The company states that each stockholder’s percentage ownership and proportional voting power remain essentially the same apart from minor changes from rounding, and the rights and privileges attached to the common stock are substantially unaffected.
GeoVax Labs, Inc. is offering 18,292,683 Common Units and 18,292,683 Pre-Funded Units, plus up to 36,585,366 shares of common stock underlying warrants, in a best efforts public sale. Each Common Unit includes one share of common stock and two five-year Common Warrants exercisable at $0.41 per share, while each Pre-Funded Unit substitutes a pre-funded warrant exercisable at $0.00001 plus two Common Warrants. The assumed public price is $0.41 per Common Unit and $0.40999 per Pre-Funded Unit, and GeoVax expects net proceeds of about $6,8 million, primarily to fund research, clinical trials, manufacturing, and working capital.
Before this deal, GeoVax had 30,058,786 shares outstanding as of December 12, 2025; this would rise to 48,351,469 shares if all Common Units are sold and no warrants are exercised. The company is a clinical-stage biotech with programs including Phase 2 trials for its COVID-19 vaccine candidate GEO-CM04S1, a planned Phase 2 study of its oncolytic therapy Gedeptin for head and neck cancer, and a GEO-MVA Mpox/smallpox vaccine expected to move directly into Phase 3 in 2026.
GeoVax reports it has never generated product revenue, incurred a net loss of approximately $17.0 million for the nine months ended September 30, 2025 and $25 million for 2024, and has received a going concern opinion from its auditors. Management warns the business requires continued external funding, highlights substantial outstanding and reserved equity (including 40,027,849 warrant shares and 2,033,648 shares reserved under stock plans), and notes significant risks around regulation, competition, intellectual property, Nasdaq listing, and potential dilution from additional equity issuance.
GeoVax Labs, Inc. (GOVX) reported the results of a special stockholder meeting held on November 26, 2025. Stockholders representing 14,125,083 of the company’s 29,705,360 issued and outstanding common shares as of September 30, 2025, were present by proxy.
Stockholders approved a proposal, required under Nasdaq listing rules, to allow the issuance of up to 11,904,768 shares of common stock upon exercise of common stock purchase warrants that were issued to certain institutional investors in a September 30, 2025 private placement. The proposal received 5,806,374 votes for, 946,094 against, and 870,973 abstentions, with 6,501,642 broker non-votes.
They also approved an amendment to the Certificate of Incorporation to implement a reverse stock split of the issued and outstanding common stock at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be set by the Board of Directors. This proposal received 11,850,760 votes for, 2,158,471 against, and 115,852 abstentions.
GeoVax Labs, Inc. filed a current report to note that it released a press release covering its operating results for the quarter ended September 30, 2025. The company states that this press release, dated November 13, 2025, is furnished as Exhibit 99.1 to the report.
The filing also includes standard forward-looking statement language, explaining that projections and expectations are subject to risks and uncertainties, and that actual results may differ from current views. The report is signed on behalf of GeoVax Labs by its Chief Financial Officer, Mark W. Reynolds.
GeoVax Labs, Inc. is supplementing a prospectus covering the resale of up to 1,605,688 shares of common stock by a selling stockholder, incorporating its latest Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
The company reported no revenue in the third quarter from its government contract after BARDA, through the ATI‑RRPV arrangement, terminated that contract for convenience. Third‑quarter 2025 results show a net loss of $6.3 million, bringing the nine‑month net loss to $17.0 million, similar to the prior year despite lower research and development spending.
GeoVax ended the period with $5.0 million in cash and cash equivalents and 29,705,360 shares outstanding, funded largely by multiple equity offerings and warrant exercises that provided about $16.0 million in net financing cash year‑to‑date. Management states that existing cash is expected to fund operations into December 2025 and that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
GeoVax Labs filed a prospectus supplement covering the resale of up to 2,170,000 shares of common stock by a selling stockholder, updating the prospectus with its Form 10‑Q for the quarter ended September 30, 2025.
In the quarter, the company reported a net loss of $6,318,914 and nine‑month net loss of $17,046,348. Revenue was $0 in Q3, reflecting the previously disclosed termination for convenience of a government contract, with $2,489,145 recognized year‑to‑date. Cash and cash equivalents were $5,008,997 and working capital was $4,693,071 as of September 30, 2025. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern, while noting plans to seek additional capital. Financing activities provided $16,041,861 in the nine months ended September 30, 2025. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs, Inc. filed a prospectus supplement updating a resale registration covering up to 1,700,000 shares of common stock by a selling stockholder and incorporating the company’s Q3 2025 Form 10‑Q.
For Q3 2025, GeoVax reported a net loss of $6,318,914 and no revenue for the quarter, with nine‑month revenue of $2,489,145 tied to its ATI‑RRPV contract prior to termination for convenience. Cash and cash equivalents were $5,008,997 as of September 30, 2025. The company states that these factors raise substantial doubt about its ability to continue as a going concern.
GeoVax completed several financings in 2025, including offerings closed on March 25, July 2, and September 30, and sales through an ATM program. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs filed a prospectus supplement for the resale of up to 975,610 shares of common stock by a selling stockholder, updating the base prospectus with its attached Q3 2025 Form 10-Q.
In the quarter, the company reported a net loss of $6,318,914 and $0 revenue, reflecting the previously disclosed termination-for-convenience of the BARDA-related ATI‑RRPV contract. For the nine months, net loss was $17,046,348. Cash and cash equivalents were $5,008,997, and working capital was $4,693,071. The company raised additional capital in March, July, and September 2025 through stock and warrant offerings and sales under its ATM program.
Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. Shares outstanding were 29,705,360 as of November 13, 2025.